ARS Pharmaceuticals, Inc. (SPRY) Misses Q2 EPS by 1c

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q2 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $500 thousand versus the consensus estimate of $1 million.

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.

You May Also Be Interested In

• Getty Realty (GTY) Reiterated at Market Outperform by Citizens on Investment Volumes
• Jefferies Starts China Oilfield Services (2883:HK) (CHOLF) at Buy
• TuHURA Biosciences (HURA) Reiterates at Market Outperform by Citizens on TBS-2025 Development